NeuroCME

This activity is expired and is no longer available for CME credit.

EXPERT INTERVIEWVIDEOCME

Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

Author(s)/Faculty:
Release Date: 2/6/2015Expiration Date: 2/5/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider: Vindico Medical Education
Dr. Guger discusses the most current research on the use of natalizumab and fingolimod to treat patients with MS.